International Journal of Hematologic Oncology

Leukemia, lymphoma and myeloma, taken together, represent the fifth most commonly occurring cancers and the second leading cause of cancer death. Symptoms of the disease are varied, with some forms of the disease being aggressive and others benign. The discovery of new targeted therapies, advances in chemotherapy and the development of new combination drugs, along with important emerging research have contributed to the significant progress made within the field of hematologic oncology in recent years.

The journal provides a forum for the discussion and analysis of emerging advancements in diagnosis, treatment strategies and novel targeted therapies, with an added focus on the overall management of hematologic malignancies and evaluation of prospects for further development.

As a bimonthly, peer-reviewed journal, International Journal of Hematologic Oncology will be a key resource for clinicians and researchers alike within the hematologic oncology community by delivering clear, concise and comprehensive articles with a high-quality format.

Articles are subject to peer-review by three independent referees on a double-blind basis. Authors publishing in the journal are asked to disclose any professional or financial interest that may be perceived as causing a conflict of interest in the context of the article. The journal welcomes unsolicited article proposals.